botox
18 December 2020Big Pharma

US ITC bars imports of low-cost Botox amid trade secrets dispute

The US International Trade Commission (ITC) has sided in favour of  AbbVie/Allergan, which argued that a rival should be prevented from importing a low-cost version of its Botox treatment into the US for 21 months, because it had stolen trade secrets.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
13 August 2019   Allergan has filed a motion asking for its “trade secrets” to be removed from evidence in a dispute over its wrinkle treatment, Botox.
Americas
4 March 2019   The US International Trade Commission has begun an investigation into Daewoong Pharmaceuticals of South Korea and California-based Evolus, following a complaint from Allergan.

More on this story

Big Pharma
13 August 2019   Allergan has filed a motion asking for its “trade secrets” to be removed from evidence in a dispute over its wrinkle treatment, Botox.
Americas
4 March 2019   The US International Trade Commission has begun an investigation into Daewoong Pharmaceuticals of South Korea and California-based Evolus, following a complaint from Allergan.

More on this story

Big Pharma
13 August 2019   Allergan has filed a motion asking for its “trade secrets” to be removed from evidence in a dispute over its wrinkle treatment, Botox.
Americas
4 March 2019   The US International Trade Commission has begun an investigation into Daewoong Pharmaceuticals of South Korea and California-based Evolus, following a complaint from Allergan.